Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib Continuation Study in SLE and DLE/SCLE
NCT06875960Phase 4Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deucravacitinib in systemic lupus erythematosus (SLE), discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE), sponsored by Bristol Myers Squibb. Primary endpoint: Number of participants treated with BMS-986165 at 2 years. Started Feb 2026; status: recruiting.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)discoid lupus erythematosus (DLE)subacute cutaneous lupus erythematosus (SCLE)
Beyond the preview
Go deeper on NCT06875960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06875960.